So, this is how I understand "reaching the primary endpoint." First though, look at one definition.
As you know when a trial reaches the primary endpoint, it means the main clinical endpoint (e.g. PFS, OS, TTP, etc) reached statistical significance.
When a trial succeeds, companies often PR that their treatment reached it's primary endpoint. When a trial fails, companies often PR that it failed to reach the primary endpoint.
So when, as you state,
That is not inconsistent with the potential for an early interim halt. Why? Because as I understand it, an interim analysis allows a trial to reach its primary endpoint early, before the end of the study.
However, you do not expect LP to predict which interim analysis will succeed, that would mean she would be forecasting success or failure at a particular interim
So when LP states September/October 2016, she means potentially reaching the primary endpoint at the end of the study as it is classically defined. In other words, she is not predicting for us whether it will end at the first, second or final analysis.